Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.66 |
| ▸ | PIK3C3 | Q8NEB9 | 2/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.36 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12341854 | 0.90 | PIK3CA (0.64) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL12339379 | 0.90 | PIK3CA (0.63) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL11898264 | 0.90 | PIK3CA (0.63) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517481 | 0.89 | PIK3CA (0.62) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517658 | 0.88 | PIK3CA (0.70) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517739 | 0.87 | PIK3CA (0.61) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1042781 | 0.87 | PIK3CA (0.69) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517696 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517708 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1517659 | 0.87 | PIK3CA (0.60) | PIK3CAPIK3C3PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | BLAQUIERE NICOLE (US) | 2013-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012488-A1 | BENZOXEPIN PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R2 | PIK3CA 1/4885PIK3C3 24/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.